Double-blind cross-over study of phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type.
Eur Neuropsychopharmacol
; 2(2): 149-55, 1992 Jun.
Article
in En
| MEDLINE
| ID: mdl-1633433
ABSTRACT
Thirty-three patients with mild primary degenerative dementia according to DSM-III (MMS between 15 and 27) took part in a double-blind cross-over study of phosphatidylserine (Fidia, 300 mg/d) versus placebo. Both treatment phases lasted for 8 weeks with an 8 week washout phase in between and a 4 week washout phase before treatment phase one. Clinical global improvement ratings showed significantly more patients improving under BC-PS than under placebo during treatment phase one. The improvement carried over to the following wash-out and treatment phases. There were no significant improvements in GBS dementia rating scale, psychometric tests or P300-latency. 16-channel EEG mapping findings indicated that the patients initially showed higher power values in all frequency bands (except alpha), when compared to a younger, healthy control group. BC-PS reduced the higher power values compared to placebo, shifting EEG power more towards the normal level.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Phosphatidylserines
/
Alzheimer Disease
Type of study:
Clinical_trials
Limits:
Aged
/
Humans
/
Middle aged
Language:
En
Journal:
Eur Neuropsychopharmacol
Journal subject:
PSICOFARMACOLOGIA
Year:
1992
Document type:
Article
Affiliation country:
Germany